Antiviral therapy

Keyphrases

Publications

volume 29, number 4, 2024

Courtney N Nichols, Mark Lustberg, Mohammed Mahdee E Sobhanie, Lucia J Niermann, Melissa Gordon, Nicholas Kman, Jonathan Parsons, Mark Conroy, Michael Dick, James Allen, Erica Reed, Joy Lehman, Carlos Malvestutto
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort. Antiviral therapy 29 (4) (2024)
Courtney N Nichols, Mark Lustberg, Mohammed Mahdee E Sobhanie, Lucia J Niermann, Melissa Gordon, Nicholas Kman, Jonathan Parsons, Mark Conroy, Michael Dick, James Allen, Erica Reed, Joy Lehman, Carlos Malvestutto
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort. Antiviral therapy 29 (4) (2024)

volume 29, number 5, 2024

Qing Zhang, Jianhua Xu, Dan Liu, Lilin Wang, Shan Ren, Sujun Zheng, Xinyue Chen, Li Qi, Junfeng Lu
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antiviral therapy 29 (5) (2024)
Shahrzad Zangooie, Reza Ghanbari, Farid Azizi Jalilian, Shahab Mahmoudvand, Ali Teimoori
Antiviral potential of phenolic compounds against HSV-1: In-vitro study. Antiviral therapy 29 (5) (2024)

volume 28, number 1, 2023

Ellen Peters, And Collins Iwuji
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. Antiviral therapy 28 (1) (2023)
André Wieringa, Peter Gj Ter Horst, GertJan Hj Wagenvoort, Birgit Cp Koch, Jasper J Haringman
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration. Antiviral therapy 28 (1) (2023)
Ellen Peters, And Collins Iwuji
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. Antiviral therapy 28 (1) (2023)
Liviawati S Wu, Yue Hu, Edward J Gane, Leen Slaets, An De Creus, Yanhua Ding, Junqi Niu, Christian Schwabe, Nele Goeyvaerts, Zhongnan Xu, Dandan Huo, Marianne Tuefferd, Inge Verbrugge, Pieter Van Remoortere, Ullrich Schwertschlag, Joris Vandenbossche
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants. Antiviral therapy 28 (1) (2023)
Ellen Peters, And Collins Iwuji
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review. Antiviral therapy 28 (1) (2023)
Liviawati S Wu, Yue Hu, Edward J Gane, Leen Slaets, An De Creus, Yanhua Ding, Junqi Niu, Christian Schwabe, Nele Goeyvaerts, Zhongnan Xu, Dandan Huo, Marianne Tuefferd, Inge Verbrugge, Pieter Van Remoortere, Ullrich Schwertschlag, Joris Vandenbossche
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants. Antiviral therapy 28 (1) (2023)
Lucero Rojas-Luna, Araceli Posadas-Modragón, Amanda M Avila-Trejo, Verónica Alcántara-Farfán, Lorena I Rodríguez-Páez, José Angel Santiago-Cruz, Marvin O Pastor-Alonso, José Leopoldo Aguilar-Faisal
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ. Antiviral therapy 28 (1) (2023)
André Wieringa, Peter Gj Ter Horst, GertJan Hj Wagenvoort, Birgit Cp Koch, Jasper J Haringman
Pharmacokinetics of zanamivir in critically ill patients undergoing continuous venovenous hemofiltration. Antiviral therapy 28 (1) (2023)
Lucero Rojas-Luna, Araceli Posadas-Modragón, Amanda M Avila-Trejo, Verónica Alcántara-Farfán, Lorena I Rodríguez-Páez, José Angel Santiago-Cruz, Marvin O Pastor-Alonso, José Leopoldo Aguilar-Faisal
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ. Antiviral therapy 28 (1) (2023)

volume 28, number 2, 2023

Fanfeng Kong, Xiao Xue Zeng
Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation. Antiviral therapy 28 (2) (2023)
Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen, Kiran Patel, Federico Hinestrosa, Edwin DeJesus
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting. Antiviral therapy 28 (2) (2023)
Fanfeng Kong, Xiao Xue Zeng
Case report and literature review: A hiccup patient developed encephalitis and duodenal perforation. Antiviral therapy 28 (2) (2023)
Tulathip Suwanlerk, Dhanushi Rupasinghe, Watsamon Jantarabenjakul, Vu T An, Jeremy L Ross, Azar Kariminia, Nguyen Van Lam, Aarti Kinikar, Pradthana Ounchanum, Thanyawee Puthanakit, Nik K Nik Yusoff, Pagakrong Lumbiganon, Kulkanya Chokephaibulkit, Do C Viet, Tavitiya Sudjaritruk, Fong S Moy, Dewi K Wati, Thahira J Mohamed, Revathy Nallusamy, Nagalingeswaran Kumarasamy, Vohith Khol, Truong H Khanh, Nia Kurniati, null null
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia. Antiviral therapy 28 (2) (2023)
Reneé De Waal, Helena Rabie, Karl-Günter Technau, Brian Eley, Nosisa Sipambo, Mark Cotton, Andrew Boulle, Robin Wood, Frank Tanser, Geoffrey Fatti, Matthias Egger, Mary-Ann Davies, null null
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antiviral therapy 28 (2) (2023)

volume 28, number 3, 2023

Wim Pierson, Marianne Tuefferd, Florence Herschke, Leen Slaets, Marjolein Crabbe, Dorien Verstappen, Steffi De Pelsmaeker, Ian Strickland, Edward J Gane, Christian Schwabe, Yingjie Zhang, Peter Meerts, Joris Vandenbossche, Pieter Van Remoortere, Inge Verbrugge, An De Creus
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults. Antiviral therapy 28 (3) (2023)
Sarah B Nahhal, Bassem Awada, Joe-David Azzo, Rayyan Wazzi-Mkahal, Souha Kanj, Zeina A Kanafani
Letter to the editor on use of antibodies from convalescent sera in the treatment of moderate and severe Covid-19 infection. Antiviral therapy 28 (3) (2023)
Nthabiseng Zilwa, Onalethata Mpejane, Golam Mehboob, Sajan S Gill, Thomas Kalinoski
Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report. Antiviral therapy 28 (3) (2023)
Ian Armstrong, Ashley Lacombe-Duncan, Mostafa Shokoohi, Yasmeen Persad, Alice Tseng, Raymond Fung, Angela Underhill, Pierre Côté, Nimâ Machouf, Adrien Saucier, Brenda Varriano, Monica Brundage, Reilly Jones, Thea Weisdorf, John Goodhew, John MacLeod, Mona Loutfy
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV. Antiviral therapy 28 (3) (2023)
Wim Pierson, Marianne Tuefferd, Florence Herschke, Leen Slaets, Marjolein Crabbe, Dorien Verstappen, Steffi De Pelsmaeker, Ian Strickland, Edward J Gane, Christian Schwabe, Yingjie Zhang, Peter Meerts, Joris Vandenbossche, Pieter Van Remoortere, Inge Verbrugge, An De Creus
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults. Antiviral therapy 28 (3) (2023)
Judith A Aberg, Anthony Mills, Santiago Moreno, Jill Slater, Manyu Prakash, Andrew Clark
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review. Antiviral therapy 28 (3) (2023)
Johan Vingerhoets, Ilse Van Dromme, Wilbert van Duijnhoven, David Anderson, Sandra De Meyer, Lorant Leopold
Genotypic and phenotypic characterization of influenza A viral variants in study participants treated with pimodivir in the phase 2b TOPAZ study. Antiviral therapy 28 (3) (2023)

volume 28, number 4, 2023

Quratulain Maqsood, Aleena Sumrin, Maryam Iqbal, Saima Younas, Nazim Hussain, Muhammada Mahnoor, Abdul Wajid
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives. Antiviral therapy 28 (4) (2023)

volume 28, number 5, 2023

Aleksandra Z Tomic, Sonja S Zafirovic, Zoran M Gluvic, Vladimir S Samardzic, Mirjana T Macvanin, Maja Lj Radunovic, Esma R Isenovic
Subacute thyroiditis following COVID-19 vaccination: Case presentation. Antiviral therapy 28 (5) (2023)
Eslam B Elkaeed, Bshra A Alsfouk, Tuqa H Ibrahim, Reem K Arafa, Hazem Elkady, Ibrahim M Ibrahim, Ibrahim H Eissa, Ahmed M Metwaly
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach. Antiviral therapy 28 (5) (2023)
Andrew Carr, Nicola E Mackie, Roger Paredes, Kiat Ruxrungtham
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective. Antiviral therapy 28 (5) (2023)
Jiachen Shen, Qiuchi Xu, Lu Chen, Xinyu Chang, Ruiting Shen, Zhenhua Zhao, Lifei Zhu, Yifei Wu, Xiaolin Hou
Andrographolide inhibits infectious bronchitis virus-induced apoptosis, pyroptosis, and inflammation. Antiviral therapy 28 (5) (2023)

volume 28, number 6, 2023

Jeff Berko, Peter Mazonson, Duncan Short, Maile Karris, Lynsay Ehui, Cassidy A Gutner, Frank Spinelli, Andrew Zolopa
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV. Antiviral therapy 28 (6) (2023)
S Jawad Zafar, Bruce L Gilliam, Sarah Ann Schmalzle
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report. Antiviral therapy 28 (6) (2023)
Nicolas A Margot, Nina Pennetzdorfer, Vidula Naik, Martin Rhee, Christian Callebaut
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. Antiviral therapy 28 (6) (2023)
Nicolas A Margot, Nina Pennetzdorfer, Vidula Naik, Martin Rhee, Christian Callebaut
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. Antiviral therapy 28 (6) (2023)
Dan Shu, Lin Cheng, Kefei Yuan, Dan Liu, He Wei
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway. Antiviral therapy 28 (6) (2023)
Nicolas A Margot, Nina Pennetzdorfer, Vidula Naik, Martin Rhee, Christian Callebaut
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA. Antiviral therapy 28 (6) (2023)

volume 27, number 6, 2022

Figen Ergur Ozturk, Ayperi Öztürk, Hale Ates
A favipiravir-induced angioedema and urticaria in a COVID-19 patient. Antiviral therapy 27 (6) (2022)
Chinyere L Nkwocha, Pamela S Carter, Somer Blair, James M Blackwell, Esther O Fasanmi
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C. Antiviral therapy 27 (6) (2022)
Chinyere L Nkwocha, Pamela S Carter, Somer Blair, James M Blackwell, Esther O Fasanmi
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C. Antiviral therapy 27 (6) (2022)
Figen Ergur Ozturk, Ayperi Öztürk, Hale Ates
A favipiravir-induced angioedema and urticaria in a COVID-19 patient. Antiviral therapy 27 (6) (2022)
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients. Antiviral therapy 27 (6) (2022)

Antiviral therapy

Keyphrases

Publications

volume 29, number 1, 2024

volume 29, number 2, 2024

volume 29, number 3, 2024

volume 29, number 4, 2024

volume 29, number 5, 2024

volume 28, number 1, 2023

volume 28, number 2, 2023

volume 28, number 3, 2023

volume 28, number 4, 2023

volume 28, number 5, 2023

volume 28, number 6, 2023

volume 27, number 6, 2022